A phase III clinical trial to evaluate the safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy children, adults, and elderly

• Main Authors: Lili Huang (Author), Ling Wang (Author), Hong Li (Author), Yuansheng Hu (Author), Weiping Ru (Author), Weixiao Han (Author), Gang Shi (Author), Qiang Ye (Author), Zhen Han (Author), Jielai Xia (Author), Shengli Xia (Author), Miao Xu (Author), Jing Li (Author)
• Format: Book
• Published: Taylor & Francis Group, 2019-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

To evaluate the safety and immunogenicity of a newly 23-valent pneumococcal polysaccharide vaccine (PPV23), a phase Ⅲ clinical trial was conducted in population aged ≥ 2 years. We conducted a randomized, double-blinded, active controlled trial, in which 1760 participants were randomly assigned in a...